Amicus Therapeutics Q1 2024 Earnings Report $8.62 -0.07 (-0.81%) As of 03/25/2025 04:00 PM Eastern Earnings HistoryForecast Amicus Therapeutics EPS ResultsActual EPS-$0.02Consensus EPS -$0.06Beat/MissBeat by +$0.04One Year Ago EPS-$0.18Amicus Therapeutics Revenue ResultsActual Revenue$110.40 millionExpected Revenue$111.19 millionBeat/MissMissed by -$790.00 thousandYoY Revenue Growth+27.90%Amicus Therapeutics Announcement DetailsQuarterQ1 2024Date5/9/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseFOLD Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads Amicus Therapeutics Earnings HeadlinesIs Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now?March 18, 2025 | msn.comAmicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)March 17, 2025 | seekingalpha.comElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.March 26, 2025 | InvestorPlace (Ad)Amicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside PotentialMarch 12, 2025 | insidermonkey.comBalanced Outlook on Amicus Therapeutics Amid Growth Ambitions and Market ChallengesMarch 7, 2025 | tipranks.comIn NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal OfficerMarch 6, 2025 | globenewswire.comSee More Amicus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amicus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amicus Therapeutics and other key companies, straight to your email. Email Address About Amicus TherapeuticsAmicus Therapeutics (NASDAQ:FOLD), a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.View Amicus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of Earnings Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
